All Oncology News

Premal H. Thaker, MD, discusses EGEN-001 in combination with pegylated liposomal doxorubicin and the potential of immunotherapy agents in ovarian and other similar cancers.

Andrew S. Chi, MD, PhD, has also been appointed co-director of the NYU Langone Brain Tumor Center.

Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.

Achieving true precision medicine with PD-1/PD-L1 agents in NSCLC will only come from biomarker-driven frontline regimens delivered to the right patients.

Andrew Hendifar, MD, discusses how PEGPH20 improved progression-free survival by 4.9 months in patients with advanced pancreatic cancer with high expression levels of hyaluronan.

Yung-Jue Bang, MD, PhD, discusses how the results of the KEYNOTE-012 study demonstrate the potential of immunotherapy in treating gastric cancer.

Pasi A. Jänne, MD, PhD, discuses the impact of gefitinib's reentry into the US market as a first-line treatment for patients with metastatic non–small cell lung cancer.

Treatment with telotristat etiprate significantly reduced the average number of daily bowel movements compared with placebo for patients with carcinoid syndrome that was not adequately controlled with a somatostatin analog.

A new drug application has been submitted for rociletinib as a treatment for patients with EGFR T790M-positive metastatic non–small cell lung cancer following prior administration of an EGFR TKI.

Clinical trial designs are undergoing a dramatic transformation geared toward the discovery and validation of new predictive biomarkers.

Corey Langer, MD, discussed the therapeutic potential for anti-HER2 agents in non–small cell lung cancer in a presentation at the 2015 International Lung Cancer Congress.

A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.

Paul Bunn, MD, discussed the latest translational advances in NSCLC at the 2015 International Lung Cancer Congress.

Highly effective next-generation therapies are currently in development for patients with oncogene-driven non–small cell lung cancer, specifically those with alterations in EGFR, ALK, ROS1, NTRK, or a variety of other gene.

The European Commission has approved the combination of pertuzumab, trastuzumab, and chemotherapy as a neoadjuvant therapy for adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer who are at high risk of recurrence.

John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

An application has been submitted to the FDA for eribulin mesylate (Halaven) as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.

OncLive's editorial and marketing groups will spread the news about the center's community outreach and research programs.

The utilization of idelalisib increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting.

Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer.

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.

The FDA has granted a breakthrough therapy designation to lenvatinib as a potential treatment for patients with advanced renal cell carcinoma who have received a VEGF-targeted therapy.

Gilles A. Salles, MD, PhD, discussed treatment regimens being developed for follicular lymphoma.

The FDA has broadened the approval of carfilzomib to include patients with relapsed multiple myeloma who have received at least one prior therapy.

The FDA has approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred.

Barbara Ann Burtness, MD, discusses the impact of two studies examining reductions in radiation and chemotherapy dose in low-risk HPV-associated oropharyngeal cancer.

Tanguy Y. Seiwert, MD, discusses the significance of the expansion results of KEYNOTE-012 for advanced squamous cell carcinoma of the head and neck.

The FDA has assigned a priority review designation to the combination of dabrafenib and trametinib for patients with unresectable or metastatic BRAFV600 mutation-positive melanoma.

A slate of 118 well-known cancer experts have signed their names to a list of recommended drug pricing reforms in hopes of curbing the soaring costs of cancer care and spurring a grassroots movement to combat the trend.